COMMUNIQUÉS West-GlobeNewswire

REVA to Hold Fourth Quarter and Full Year 2017 Financial Results Call

01/03/2018 - 01:45

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX:RVA) (“REVA” or the “Company”) has scheduled a conference call to review its fourth quarter and full year 2017 financial results and provide a [...]

Agility Health Closes Proposed Transaction with Alliance

01/03/2018 - 01:03

GRAND RAPIDS, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Agility Health, Inc. (TSXV:AHI) (“Agility Health” or the “Company”) announced today that it closed its previously announced transaction with Alliance Physical [...]

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

01/03/2018 - 00:00

CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ: SRPT ), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to [...]

Extendicare Announces 2017 Year End Results

28/02/2018 - 23:00

MARKHAM, Ontario, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE ) today reported results for the fourth quarter and year ended December 31, 2017. Results are presented in [...]

Galectin Therapeutics to Present at 30th Annual ROTH Conference

28/02/2018 - 22:35

NORCROSS, Ga., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ: GALT ), the leading developer of therapeutics that target galectin proteins, today announced that Peter G. Traber, M.D., the Company’s [...]

Retrophin to Present at the Barclays Global Healthcare Conference

28/02/2018 - 22:30

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX ) today announced that Stephen Aselage, chief executive officer, will present at the Barclays Global Healthcare Conference in Miami on Wednesday [...]

Intellia Therapeutics to Present at March Healthcare Investor Conferences

28/02/2018 - 22:30

CAMBRIDGE, Mass., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will [...]

Alimera Sciences Reports Fourth Quarter and Full Year 2017 Financial Results

28/02/2018 - 22:30

GAAP Net Loss cut by 34% from $33.2 in 2016 to $22.0 million in 2017 Adjusted EBITDA loss reduced by 61% from $22.8 million in 2016 to $8.8 million 2017 Filed for Type II variation for uveitis in Europe for ILUVIEN in [...]

TearLab Osmolarity System Launches in Brazil

28/02/2018 - 22:30

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TearLab Corporation (OTCQB:TEAR) (TSX: TLB ) (“TearLab” or the “Company”) today announced that it plans to launch the TearLab Osmolarity System at the 2018 Simpósio [...]

Corium Announces Proposed Offering of $100 Million of Convertible Senior Notes; Receives FDA Feedback on Pilot Bioequivalence Study

28/02/2018 - 22:15

MENLO PARK, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI ), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty [...]

Zomedica Pharmaceuticals Corp. Announces Year End 2017 Financial Results

28/02/2018 - 22:11

ANN ARBOR, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American:ZOM) (TSX-V: ZOM ) (“Zomedica” or “Company”), a veterinary diagnostic and pharmaceutical company, today reported [...]

Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

28/02/2018 - 22:10

- Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and Improved Motor Function - - Multiple Additional Data Readouts from SCiStar Study Expected in 2018 into First Quarter of 2019 [...]

Clementia Reports 2017 Operating Results and Business Highlights

28/02/2018 - 22:05

Enrollment Underway in Palovarotene Phase 3 MOVE Trial for Fibrodysplasia Ossificans Progressiva (FOP) On-track to Enroll First Patient in Palovarotene Phase 2 MO-Ped Trial for Multiple Osteochondromas (MO) this Quarter [...]

Clementia annonce ses résultats financiers et faits saillants de 2017

28/02/2018 - 22:05

Recrutement en cours pour l'essai clinique de phase 3 MOVE sur le palovarotene chez les patients atteints de fibrodysplasie ossifiante progressive (FOP) En voie de recruter un premier patient pour l'essai de phase 2 MO- [...]

SeaSpine Announces Fourth Quarter and Full-Year 2017 Results and Issues 2018 Financial Guidance

28/02/2018 - 22:05

CARLSBAD, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- SeaSpine Holdings Corporation (NASDAQ: SPNE ), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, announced today [...]

TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update

28/02/2018 - 22:05

SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON ), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer [...]

Fulgent Genetics Reports Fourth Quarter and Full Year 2017 Financial Results

28/02/2018 - 22:05

Fourth Quarter of 2017 Results : Revenue of $4.3 million GAAP loss of $1.8 million, or $0.10 per share Non-GAAP loss of $1.0 million, or $0.06 per share Adjusted EBITDA loss of $952,000 Full Year 2017 Results : Revenue [...]

K2M Group Holdings, Inc. Reports Fourth Quarter and Full Year 2017 Financial Results

28/02/2018 - 22:05

LEESBURG, Va., Feb. 28, 2018 (GLOBE NEWSWIRE) -- K2M Group Holdings, Inc. (Nasdaq: KTWO ) (the “Company” or “K2M”), a global leader of complex spine and minimally invasive solutions focused on achieving three- [...]

BeiGene Reports Fourth Quarter and Full Year 2017 Financial Results

28/02/2018 - 22:05

CAMBRIDGE, Mass. and BEIJING, China, Feb. 28, 2018 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE ), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly [...]